Breast cancer
HR+/HER2-, HER2-low and TNBC: CDK4/6, oral SERDs, PI3K pathway and TROP2 ADCs.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 40 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for breast carcinoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 10 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | genetic literature | Pathways | Literature | Animal models | Clinical | RNA expr. |
|---|---|---|---|---|---|---|---|---|---|
| BRCA1 BRCA1 DNA repair associated | 0.91 | 0.96 | 0.90 | ||||||
| BRCA2 BRCA2 DNA repair associated | 0.91 | 0.95 | 0.88 | ||||||
| PALB2 partner and localizer of BRCA2 | 0.87 | 0.96 | 0.84 | ||||||
| TP53Peds RMTL tumor protein p53 | 0.86 | 0.89 | 0.95 | ||||||
| ATMPeds RMTL ATM serine/threonine kinase | 0.86 | 0.94 | 0.65 | ||||||
| CHEK2 checkpoint kinase 2 | 0.85 | 0.95 | 0.61 | ||||||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.85 | 0.81 | 0.95 | ||||||
| RAD51C RAD51 paralog C | 0.82 | 0.91 | 0.69 | ||||||
| ESR1 estrogen receptor 1 | 0.82 | 0.69 | 0.84 | ||||||
| CDH1 cadherin 1 | 0.82 | 0.93 | 0.91 | ||||||
| ERBB2Peds RMTL erb-b2 receptor tyrosine kinase 2 | 0.82 | – | 0.83 | ||||||
| AKT1 AKT serine/threonine kinase 1 | 0.81 | 0.55 | 0.89 | ||||||
| BARD1 BRCA1 associated RING domain 1 | 0.80 | 0.87 | 0.70 | ||||||
| PTENPeds RMTL phosphatase and tensin homolog | 0.79 | 0.78 | 0.90 | ||||||
| RAD51D RAD51 paralog D | 0.78 | 0.87 | 0.65 | ||||||
| BRIP1 BRCA1 interacting DNA helicase 1 | 0.77 | 0.95 | 0.89 | ||||||
| FGFR2 fibroblast growth factor receptor 2 | 0.77 | 0.75 | 0.65 | ||||||
| MAP3K1 mitogen-activated protein kinase kinase kinase 1 | 0.77 | 0.58 | 0.93 | ||||||
| TBX3 T-box transcription factor 3 | 0.76 | 0.67 | 0.90 | ||||||
| GATA3 GATA binding protein 3 | 0.74 | – | 0.84 | ||||||
| MAP2K4 mitogen-activated protein kinase kinase 4 | 0.72 | 0.23 | 0.91 | ||||||
| FOXA1 forkhead box A1 | 0.72 | – | 0.90 | ||||||
| KMT2C lysine methyltransferase 2C | 0.72 | – | 0.93 | ||||||
| KRAS KRas proto-oncogene, GTPase | 0.71 | 0.84 | 0.70 | ||||||
| POLD1 DNA polymerase delta 1, catalytic subunit | 0.71 | 0.19 | 0.63 | ||||||
| NCOR1 nuclear receptor corepressor 1 | 0.70 | 0.18 | 0.90 | ||||||
| TERTPeds RMTL telomerase reverse transcriptase | 0.70 | 0.76 | 0.84 | ||||||
| CBFB core-binding factor subunit beta | 0.70 | – | 0.90 | ||||||
| CDK6Peds RMTL cyclin dependent kinase 6 | 0.70 | – | 0.87 | ||||||
| POLE DNA polymerase epsilon, catalytic subunit | 0.69 | 0.19 | 0.70 | ||||||
| NF1 neurofibromin 1 | 0.69 | 0.61 | 0.85 | ||||||
| PPM1DPeds RMTL protein phosphatase, Mg2+/Mn2+ dependent 1D | 0.69 | 0.70 | 0.75 | ||||||
| FBXO11 F-box protein 11 | 0.69 | 0.90 | 0.86 | ||||||
| ERBB4 erb-b2 receptor tyrosine kinase 4 | 0.69 | 0.44 | 0.76 | ||||||
| CDK4Peds RMTL cyclin dependent kinase 4 | 0.68 | – | 0.63 | ||||||
| ARID1A AT-rich interaction domain 1A | 0.68 | – | 0.86 | ||||||
| RAD51B RAD51 paralog B | 0.67 | 0.62 | 0.88 | ||||||
| RND2 Rho family GTPase 2 | 0.67 | 0.97 | 0.55 | ||||||
| EBF1 EBF transcription factor 1 | 0.67 | 0.78 | 0.88 | ||||||
| MSH6 mutS homolog 6 | 0.67 | 0.90 | 0.70 | ||||||
| MLH1 mutL homolog 1 | 0.67 | 0.90 | 0.70 | ||||||
| CUX1 cut like homeobox 1 | 0.66 | 0.54 | 0.76 | ||||||
| MSH2 mutS homolog 2 | 0.66 | 0.90 | 0.70 | ||||||
| EGFRPeds RMTL epidermal growth factor receptor | 0.66 | 0.19 | 0.56 | ||||||
| FOXP1 forkhead box P1 | 0.66 | 0.51 | 0.76 | ||||||
| SETBP1 SET binding protein 1 | 0.66 | 0.77 | 0.88 | ||||||
| NBN nibrin | 0.66 | 0.89 | 0.69 | ||||||
| AR androgen receptor | 0.66 | – | 0.75 | ||||||
| RAD50 RAD50 double strand break repair protein | 0.65 | 0.89 | 0.71 | ||||||
| PMS2 PMS1 homolog 2, mismatch repair system component | 0.65 | 0.89 | 0.68 |
59 biomarkers in Breast cancer have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Breast Cancer”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 318 accepted items exist; the first 100 were read. This is the published evidence, not treatment advice.
- ERBB2 Amplification level A
- BRCA1 Loss-of-function level A
- BRCA2 Loss-of-function level A
- ESR1 Mutation level A
- PIK3CA Mutation level A
- PIK3CA C420R level A
- PIK3CA E453K OR PIK3CA E453Q OR PIK3CA E453A OR PIK3CA E453D OR PIK3CA E453G OR PIK3CA E453V level A
- PIK3CA E542K level A
- PIK3CA E542K OR PIK3CA E542Q OR PIK3CA E542A OR PIK3CA E542D OR PIK3CA E542G OR PIK3CA E542R OR PIK3CA E542V level A
- PIK3CA E545K OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545D level A
- PIK3CA E545K OR PIK3CA E545Q OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545V OR PIK3CA E545D OR PIK3CA E545L OR PIK3CA E545R level A
- PIK3CA G1049S OR PIK3CA G1049R OR PIK3CA G106V OR PIK3CA G106R OR PIK3CA G1049A OR PIK3CA G106S OR PIK3CA G106A OR PIK3CA G106D OR PIK3CA G118D OR PIK3CA G1049C OR PIK3CA G1049D level A